Picard Medical, INC 8-K filings

Picard Medical has received acceptance from NYSE American for its plan to regain compliance with continued listing standards, allowing it to maintain its listing while executing strategic initiatives.

Picard Medical, Inc. announced that its stockholders approved all matters put forth at the Annual Meeting, including director elections, executive compensation, and a reverse stock split.

Picard Medical releases annual stockholder presentation detailing strong Q1 revenue growth, product development milestones for the Emperor platform, and proposals for the upcoming 2026 Annual Meeting.

Picard Medical discusses Q1 growth, next-gen artificial heart tech, and proposals including a reverse stock split to address NYSE listing concerns.

Picard Medical releases its 2026 Annual Stockholder Presentation highlighting business progress, product development, and upcoming meeting proposals.

Picard Medical, Inc. announced the appointment of Dr. Joe Xiao to its Board of Directors, effective June 23, 2026.

Picard Medical announces the departure of CEO Patrick NJ Schnegelsberg and the appointment of Chairman Dr. Richard Fang as Interim CEO.

Picard Medical, Inc. announced the appointment of Georgina Smith as Chief Accounting Officer and the immediate termination of CFO Bernard Skaggs, effective June 1, 2026.

Picard Medical, Inc. issued a letter to shareholders detailing significant financial improvements, progress on its next-generation artificial heart, and plans to address NYSE American listing requirements.

Picard Medical announced first quarter 2026 financial results, including positive gross profit and revenue growth, while also addressing notices from NYSE American regarding continued listing standards and a plan to regain compliance.

Picard Medical, Inc. announced the closing of a registered public offering, raising approximately $5.0 million before expenses through the sale of common stock and warrants.

Picard Medical, Inc. has exchanged existing warrants for new ones with a lower exercise price and announced the pricing of a $5 million offering, including common stock and new warrants.

Picard Medical announced preliminary Q1 2026 revenue surged 79.9% to $1.1 million, driven by increased total artificial heart utilization and pricing adjustments.

Picard Medical, Inc. has entered into a securities purchase agreement for a $555,555.56 convertible promissory note with Quick Capital, LLC, receiving $490,000 in funding.

Picard Medical, Inc. announced its full-year 2025 financial results, reporting a 12.5% revenue increase and a strengthened balance sheet following its public listing.

Picard Medical, Inc. announced it will present preclinical data for its fully implantable Emperor Total Artificial Heart at the American College of Cardiology's Annual Scientific Session & Expo.

Picard Medical announced a successful case where its SynCardia Total Artificial Heart supported a patient for 119 days before a successful heart transplant at UCSF Health.

Picard Medical announces a 29-year-old patient successfully received a heart transplant after 1,636 days of support from the SynCardia Total Artificial Heart.

Picard Medical, Inc. stockholders approved a significant increase in authorized shares and the issuance of new common stock to facilitate future capital raising.

Picard Medical, Inc. announced its SynCardia Total Artificial Heart and next-generation technology will be featured on BTV Business Television, airing on FOX Business News.

Picard Medical's VP of Clinical Affairs will present new data on its SynCardia Total Artificial Heart and next-generation Emperor system at a major heart failure conference.

Picard Medical, Inc. announced its SynCardia subsidiary will participate in a hands-on training day at the Technology and Heart Failure Therapeutics 2026 conference to expand adoption of its total artificial heart therapy.

Picard Medical, parent company of SynCardia Systems, announced the launch of the 'Cruxx to MedTech Podcast' series, exploring its SynCardia Total Artificial Heart and the next-generation Emperor device.

Picard Medical, Inc. presents its investor overview, emphasizing SynCardia's FDA-approved Total Artificial Heart and its strategic growth initiatives.

Picard Medical, parent of SynCardia Systems, has secured up to $50 million in senior secured notes and warrants to bolster working capital and general corporate purposes.

Picard Medical, Inc. celebrated its transition to the public markets by ringing the NYSE Opening Bell on December 18, 2025, highlighting its leadership in total artificial heart technology.

Picard Medical announces a patient has lived over eight years with its SynCardia Total Artificial Heart, setting a new world record for continuous support.

Picard Medical's SynCardia subsidiary presented positive in vitro and acute in vivo data for its next-generation, fully implantable Emperor Total Artificial Heart at a major medical conference.

Picard Medical's CEO, Patrick NJ Schnegelsberg, will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany, on December 6, 2025.

Picard Medical, Inc. has secured a $1 million unsecured promissory note from an affiliate of its Chairman to address short-term liquidity and fund operations.